Navigation Links
First do no harm? UH prof taking opposite approach to treat asthma
Date:4/9/2008

HOUSTON, April 9, 2008 One month of tough breathing may help asthma sufferers breathe easier in the long run, according to research from one University of Houston professor.

In a move that challenges one of the most basic tenets of the Hippocratic Oath first do no harm Richard Bond, associate professor of pharmacology at UH, is relying on a long-standing medical taboo to treat asthma. Although counterintuitive, Bonds studies are reminiscent of hair-of-the-dog folk wisdom to treat like with like, in this case using beta blockers (or antagonists) instead of stimulants (or agonists) in asthmatics.

Coining the term paradoxical pharmacology treating patients with medicine that initially worsens their symptoms before eventually improving their overall health Bond first applied this hypothesis in studies with mice and then moved on to two clinical trials with humans. Currently in the second clinical trial, the part of this research analyzing mice was recently published in the American Journal of Respiratory Cell and Molecular Biology, which cited the relevance of Bonds work as possibly leading to a paradigm shift in the treatment of asthma. The results of the first human trial were also recently published in Pulmonary Pharmacology and Therapeutics.

Acute asthma attacks have traditionally been treated with inhaler-type stimulant drugs that open constricted airways. Giving beta blockers to asthmatics has long been thought to be contraindicated, because their acute use may cause increased airway resistance. While the use of beta-stimulants is known to provide temporary relief, their effectiveness declines over time.

Bonds tests initially done on asthmatic mice and later replicated in his first clinical trial with humans showed that while beta blockers initially made breathing problems worse, their continued use resulted in improved respiratory function after a 28-day period. These longer-term effects demonstrate th
'/>"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
Source:Eurekalert  

Page: 1 2 3 4

Related medicine news :

1. Ventas Announces 2008 First Quarter Earnings Release Date and Conference Call
2. Study: Treating post-traumatic stress first helps children overcome grief
3. Advancing Interoperability - Nonin(R) Medical Unveils Worlds First Bluetooth(R)-Enabled, Wireless Fingertip Pulse Oximeter
4. Albemarle Corporations First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET
5. VNUS Medical Technologies to Report First-Quarter 2008 Results and Webcast Teleconference on April 21
6. Albemarle Corporations First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 9:00am ET
7. GetWellNetwork Kicks Off GetConnected2008, First Annual Users Conference
8. Barr Will Host An Earnings Conference Call on May 8, 2008 to Discuss the Results for the First Quarter of Calendar 2008
9. Stiefel Laboratories Appoints First Chief Scientific Officer
10. Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call
11. Exponent to Report First Quarter Fiscal 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
First do no harm? UH prof taking opposite approach to treat asthma
First do no harm? UH prof taking opposite approach to treat asthma
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2Be overweight and live longer 59643 1Springer and WINFOCUS found new journal 59641 1Springer and WINFOCUS found new journal 59641 2New findings on the formation of body pigment 59639 1